Rennova Health Inc
Stellar Biotechnologies’ Partner Neovacs’s Favorable Study Data
Today, Stellar Biotechnologies’ stock was up ~10.5% in premarket trading as the company issued a statement on positive study results published by its partner Neovacs.
Why Stellar Biotechnologies Saw Pre-Market Gains of 84%
Stellar Biotechnologies rose ~84% in the pre-market session today on the news of successful completion of a study related to the company’s KLH products.